A Lucrative Opportunity At The $50 Billion Intersection Of Biotech And Cannabis
The company featured in today’s article finds itself at the intersection of biotech and cannabis – an intersection that could be worth $50 billion by 2029.
Pharmaceutical Stocks
Unmet Needs And Niche Markets: These Pharma Stocks Have The Momentum
While the surge in interest in pharmaceutical stocks this year has been primarily driven by factors related to the COVID-19 pandemic, the author of today’s article advises that “companies working on pharmaceutical products for unmet needs or other niche markets such as animal health could be worth a closer look.”